- Home
- REGN vs DB Comparison
REGN vs DB Comparison
Compare REGN & DB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- DB
- Stock Information
- Founded
- REGN 1988
- DB 1870
- Country
- REGN United States
- DB Germany
- Employees
- REGN N/A
- DB N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- DB Major Banks
- Sector
- REGN Health Care
- DB Finance
- Exchange
- REGN Nasdaq
- DB Nasdaq
- Market Cap
- REGN 59.5B
- DB 68.9B
- IPO Year
- REGN 1991
- DB N/A
- Fundamental
- Price
- REGN $654.37
- DB $36.23
- Analyst Decision
- REGN Buy
- DB Sell
- Analyst Count
- REGN 21
- DB 3
- Target Price
- REGN $779.00
- DB N/A
- AVG Volume (30 Days)
- REGN 1.0M
- DB 2.2M
- Earning Date
- REGN 10-28-2025
- DB 10-29-2025
- Dividend Yield
- REGN 0.55%
- DB 1.55%
- EPS Growth
- REGN 2.88
- DB 49.43
- EPS
- REGN 41.59
- DB 2.91
- Revenue
- REGN $14,247,800,000.00
- DB $35,036,958,821.00
- Revenue This Year
- REGN $1.34
- DB $12.90
- Revenue Next Year
- REGN $5.23
- DB $2.70
- P/E Ratio
- REGN $15.49
- DB $11.75
- Revenue Growth
- REGN 2.89
- DB 10.83
- 52 Week Low
- REGN $476.49
- DB $16.02
- 52 Week High
- REGN $844.51
- DB $37.86
- Technical
- Relative Strength Index (RSI)
- REGN 67.60
- DB 59.69
- Support Level
- REGN $625.14
- DB $35.65
- Resistance Level
- REGN $664.00
- DB $36.28
- Average True Range (ATR)
- REGN 17.50
- DB 0.47
- MACD
- REGN 4.95
- DB 0.28
- Stochastic Oscillator
- REGN 89.45
- DB 84.54
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About DB Deutsche Bank AG
Deutsche Bank is a universal bank operating on a global scale. The bank offers corporate, retail, investment banking, private banking, and asset management to its clients.